Eagle Pharmaceuticals Inc Net Assets
Eagle Pharmaceuticals Inc net assets. Based on the latest financial reports, Eagle Pharmaceuticals Inc (EGRX) has net assets worth $252.04 Million USD as of June 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($404.82 Million) and total liabilities ($152.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore EGRX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $252.04 Million |
| % of Total Assets | 62.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | 45.28% |
| 10-Year Change | 11271.06% |
| Growth Volatility | 466.57 |
Net Assets of Eagle Pharmaceuticals Inc (2012–2022)
Net assets of Eagle Pharmaceuticals Inc from 2012 to 2022. This chart illustrates how Eagle Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See EGRX net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Eagle Pharmaceuticals Inc (2012–2022)
The table below shows the annual net assets of Eagle Pharmaceuticals Inc from 2012 to 2022. For live market cap and overall valuation, see EGRX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $233.56 Million | +32.36% |
| 2021-12-31 | $176.45 Million | -5.14% |
| 2020-12-31 | $186.01 Million | +3.82% |
| 2019-12-31 | $179.17 Million | +11.45% |
| 2018-12-31 | $160.76 Million | -10.26% |
| 2017-12-31 | $179.14 Million | +18.46% |
| 2016-12-31 | $151.23 Million | +67.39% |
| 2015-12-31 | $90.34 Million | +172.97% |
| 2014-12-31 | $33.10 Million | +1511.31% |
| 2013-12-31 | $2.05 Million | +116.98% |
| 2012-12-31 | $-12.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eagle Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 20704140300.0% over the analyzed period, indicating profitable operations and earnings retention.
- The company has 104.1% of equity in treasury stock, representing shares repurchased from the open market.
Eagle Pharmaceuticals Inc Net Assets Breakdown (December 2022)
Eagle Pharmaceuticals Inc net assets breakdown by equity component as of December 2022.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $111.50 Million | 47.74% |
| Common Stock | $18.00K | 0.01% |
| Treasury Stock | $243.12 Million | 104.09% |
| Other Comprehensive Income | $-1.11 Million | -0.48% |
| Other Components | $366.26 Million | 156.82% |
| Total Equity | $233.56 Million | 100.00% |
Eagle Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Eagle Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Linkage Global Inc
NASDAQ:UZX
|
$3.29 Million |
|
Marvel Discovery Corp
V:MARV
|
$3.29 Million |
|
Kedaung Indah Can Tbk
JK:KICI
|
$3.30 Million |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
$3.30 Million |
|
Thunderstruck Resources Ltd
V:AWE
|
$3.29 Million |
|
Golden Sky Minerals Corp
V:AUEN
|
$3.29 Million |
|
New Zealand Coastal Seafoods Ltd
AU:NZS
|
$3.28 Million |
|
Property Franchise Group PLC
LSE:TPFG
|
$3.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eagle Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 176,453,000 to 233,560,000, a change of 57,107,000 (32.4%).
- Net income of 35,642,000 contributed positively to equity growth.
- Dividend payments of 1,747,000 reduced retained earnings.
- Share repurchases of 18,004,000 reduced equity.
- Other comprehensive income decreased equity by 1,018,000.
- Other factors increased equity by 42,234,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $35.64 Million | +15.26% |
| Dividends Paid | $1.75 Million | -0.75% |
| Share Repurchases | $18.00 Million | -7.71% |
| Other Comprehensive Income | $-1.02 Million | -0.44% |
| Other Changes | $42.23 Million | +18.08% |
| Total Change | $- | 32.36% |
Book Value vs Market Value Analysis
This analysis compares Eagle Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.07x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-1.14 | $1.29 | x |
| 2013-12-31 | $0.19 | $1.29 | x |
| 2014-12-31 | $3.32 | $1.29 | x |
| 2015-12-31 | $5.56 | $1.29 | x |
| 2016-12-31 | $9.20 | $1.29 | x |
| 2017-12-31 | $11.26 | $1.29 | x |
| 2018-12-31 | $10.52 | $1.29 | x |
| 2019-12-31 | $12.67 | $1.29 | x |
| 2020-12-31 | $13.51 | $1.29 | x |
| 2021-12-31 | $13.52 | $1.29 | x |
| 2022-12-31 | $17.88 | $1.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eagle Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.26%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.26%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.74x
- Recent ROE (15.26%) is above the historical average (-19.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -763.41% | 0.27x | 0.00x | $-18.17 Million |
| 2013 | -294.47% | -44.22% | 0.76x | 8.81x | $-6.25 Million |
| 2014 | -54.32% | -94.13% | 0.36x | 1.61x | $-21.29 Million |
| 2015 | 2.85% | 3.88% | 0.53x | 1.38x | $-6.46 Million |
| 2016 | 53.86% | 42.99% | 0.89x | 1.41x | $66.33 Million |
| 2017 | 29.00% | 21.94% | 0.88x | 1.51x | $34.03 Million |
| 2018 | 19.84% | 14.96% | 0.89x | 1.48x | $15.83 Million |
| 2019 | 7.99% | 7.31% | 0.77x | 1.42x | $-3.60 Million |
| 2020 | 6.45% | 6.38% | 0.74x | 1.36x | $-6.61 Million |
| 2021 | -4.89% | -5.03% | 0.68x | 1.44x | $-26.27 Million |
| 2022 | 15.26% | 11.26% | 0.78x | 1.74x | $12.29 Million |
Industry Comparison
This section compares Eagle Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $100,165,415
- Average return on equity (ROE) among peers: -25.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eagle Pharmaceuticals Inc (EGRX) | $252.04 Million | 0.00% | 0.61x | $3.29 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $166.09 Million | -138.50% | 2.72x | $143.73 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $562.47K |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $189.26 Million |
| Alkermes Plc (ALKS) | $161.37 Million | -10.45% | 1.50x | $7.61 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $3.22 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $85.19 Million | 5.07% | 0.51x | $279.44 Million |
About Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non… Read more